Introduction
============

Systemic sclerosis (SSc) is a systemic autoimmune, connective tissue disease characterized by inflammation, vascular endothelial dysfunction, specific immunologic abnormalities, and tissue fibrosis due to an imbalance between collagen production and degradation. Although its phenotypic characteristics are heterogeneous and disease course variable, two different clinical subtypes can be identified, the limited cutaneous form (lSSc) and the diffuse cutaneous form of SSc (dSSc). The lSSc subset is characterized by skin thickening of the face, neck, and distal aspects of the limbs, by ischemic digital loss, and an increased prevalence of isolated pulmonary hypertension. The dSSc subset involves skin of the proximal limbs as well and affects visceral organs, including the lung, heart, gastrointestinal tract, and kidneys, especially at late stages. The prevalence of SSc in females is higher than in males and in blacks than in whites ([@b42-btt-2-389]). The average age at diagnosis is lower for blacks than for whites, and blacks have about a twice higher chance to develop dSSc. A positive family history is the strongest risk factor for SSc, although the absolute risk for each family member remains low ([@b2-btt-2-389]).

SSc is believed to be caused by the interaction of genetic and environmental factors ([@b30-btt-2-389]; [@b1-btt-2-389]; [@b13-btt-2-389]), leading to a loss of immune tolerance. T and B lymphocytes are responsible for the establishment and maintenance of tolerance as illustrated by the observation that alterations in B cell signaling result in autoimmunity. B cell signaling is modulated by response regulators, such as CD19 ([@b23-btt-2-389]; [@b12-btt-2-389]). For example, combined binding of CD19 with the antigen-receptor of B lymphocytes decreases the antigen receptor-stimulation threshold a 100-fold ([@b10-btt-2-389]). CD19 can also form a complex with CD21, the receptor for fragments of the third complement component (C3), which amplifies the BCR-signal. This binding of C3 to the CD19--CD21 complex links innate with humoral immunity ([@b60-btt-2-389]). CD22 is a negative regulator of the BCR complex, terminating signal transduction ([@b4-btt-2-389]). Both CD19 and CD22 have their own regulatory network for the BCR complex; CD19 expression causes CD22 phosphorylation, while CD22 expression is responsible for the inhibition of CD19 ([@b18-btt-2-389]; [@b20-btt-2-389]). This CD19/CD22 loop suggests a regulation-balance of autoimmunity in B cells. In keeping with this, transgenic mice overexpressing CD19 showed increased serum levels of autoantibodies, indicating that CD19 overexpression disrupts tolerance in B cells ([@b29-btt-2-389]). Interestingly, CD22 deficient mice also had increased levels of autoantibodies indicating that CD22 deficiency alone is sufficient to induce autoimmunity ([@b44-btt-2-389]).

Whatever the precise abnormal immunological mechanism underlying SSc, the aforementioned studies do illustrate how subtle B cell abnormalities lead to survival and activation of self-reactive B cells, production of autoantibodies and autoimmune disease ([@b38-btt-2-389]; [@b70-btt-2-389]).

Pathological features of SSc
============================

Dermal fibrosis typically starts in the extremities with an inflammatory phase characterized by mononuclear infiltration ([@b17-btt-2-389]), which will then progress to fibrosis. Although the exact process is not known, it is suggested that as inflammation subsides, fibrosis increases ([@b50-btt-2-389]). In the skin, thickening of the dermis is found showing accumulation of dense collagen, whereas in the lower dermis small vessels showed fibrous thickening ([@b16-btt-2-389]; [@b30-btt-2-389]). An early study on skin biopsies, using hematoxylin and eosin (H&E) stainings, showed cellular infiltrates consisting of lymphocytes, plasma cells, and macrophages in 49% of 65 SSc patients ([@b16-btt-2-389]). [@b28-btt-2-389] confirmed the presence of increased numbers of histiocytes, eosinophils, and neutrophils in lesional skin of patients with SSc compared with the normal skin of healthy controls using H&E stainings. Of note, immunohistochemical (IHC) analysis showed no CD20^+^ B cells in these patients. A recent study, however, did show CD20^+^ B cells in 3 skin biopsies from 8 control SSc patients, although in the skin biopsies from 4 SSc patients treated with anti-CD20 monoclonal antibody no CD20^+^ B cells were detected. CD3^+^ T cells were found in all tissue samples ([@b8-btt-2-389]). In our own hands abundant expression of CD79a^+^ B cells can be detected in the dermis of SSc patients ([Figure 1](#f1-btt-2-389){ref-type="fig"}). A mononuclear infiltrate was also detected by others using IHC in pulmonary tissue samples from SSc patients with interstitial lung disease (ILD) showing the presence of CD20^+^ B cells, CD3^+^ T cells, and CD68^+^ macrophages ([@b36-btt-2-389]). Plasma cells were not stained in this study. A gene expression study on SSc skin samples provided further evidence for a prominent role of B cells ([@b66-btt-2-389]). Gene clusters involving groups of genes characteristically expressed in endothelial cells, B lymphocytes, those associated with synthesis of extracellular matrix, and genes expressed in T cells were highly expressed in tissue from the SSc patients when compared to healthy controls. Gene expression from skin biopsies showed prominent gene expression (immunoglobulins and CD53 genes) associated with B-lymphocytes, including plasma cells, indicating that the mononuclear cell infiltrates consist of a variety of cells.

Autoantibodies in SSc
=====================

Autoantibodies are present in 95% of SSc patients, and are either specific for SSc or have overlap with other connective diseases ([@b43-btt-2-389]). The autoantibodies antitopoisomerase 1 (anti-Topo 1, Scl-70), anti-RNA polymerase III, and anti-U3 RNP are associated with dSSc, whereas others, like anticentromere, anti-U1 RNP, anti-PmScl, and anti-Th/To are associated with lSSc. The incidence rates of these auto-antibodies vary among different ethnic groups ([@b34-btt-2-389]; [@b46-btt-2-389]). In a study of 1,432 cases from the Pittsburgh Scleroderma Databank, 10-year survival was linked to autoantibody status. In patients with lSSC the 10-year survival was 75% in patients positive for anticentromere antibody, 88% for those with anti-U1 RNP, 72% in those with anti-PmScl, and 65% in patients with anti-Th/To autoantibodies. For dSSC patients the 10-year survival was 64% for patients with anti-Topo 1, 75% for patients with anti-RNA polymerase III, and 61% in those with anti-U3 RNP autoantibodies ([@b58-btt-2-389]). Different autoantibodies are associated with different clinical manifestations. ILD is associated with anti-Topo 1, pulmonary hypertension with anticentromere antibodies, anti-3U RNP, and antiTh/To, whereas renal hypertension is associated with RNA polymerase III antibodies ([@b43-btt-2-389]).

Anti-Topo1 is the most common autoantibody (10%--30%) in dSSc ([@b59-btt-2-389]; [@b33-btt-2-389]). Its serum levels correlate positively with disease activity and disease severity in SSc ([@b27-btt-2-389]). Moreover, loss of anti-Topo 1 has been associated with clinical improvement ([@b35-btt-2-389]).

More recently, other autoantibodies have been detected in the sera of SSc patients ([@b3-btt-2-389]). These include antiendothelial cell antibodies (AECAs), antifibrillin-1 (anti-FBN1) antibodies, antibodies against matrix metalloproteinases (MMP), and antiplatelet-derived growth factor receptor (PDGFR) antibodies. Some of the AECAs have been shown to bind to the human cytomegalovirus late protein UL94, and induce endothelial cell apoptosis via the interaction with the cell surface integrin-NAG-2 protein complex ([@b40-btt-2-389]). Anti-FBN1 antibodies activate normal fibroblasts resulting in the increased production of ECM components ([@b72-btt-2-389]). Anti-PDGFR autoantibodies induce collagen 1 production by reactive oxygen species cascades, and convert resting fibroblasts into myofibroblasts ([@b5-btt-2-389]). Further autoantibodies found in SSc patients include antifibroblast antibodies (AFA), which are capable of binding to the surface of fibroblasts ([@b11-btt-2-389]), and autoantibodies against the molecular chaperone heat-shock protein 47 (HSP47) ([@b19-btt-2-389]). The presence of circulating, potentially functional, autoantibodies argues in favor of a pathogenic role of B cells in SSc.

Other immunological abnormalities in SSc
========================================

B cells, among other cells, secrete interleukin-6 (IL-6), which stimulates fibroblasts to produce collagen. In a mouse scleroderma model, B cell depletion using an anti-mouse CD20 monoclonal antibody led to a decrease in IL-6 mRNA levels and a reduction of fibrosis ([@b26-btt-2-389]). IL-6 serum levels and spontaneous IL-6 production by peripheral blood mononuclear cells (PBMCs) are higher in SSc patients compared with normal controls. In addition, it was shown that IL-6 serum levels correlate with skin fibrosis ([@b53-btt-2-389]). Thus, IL-6 may be an important target for the treatment of SSc in humans. Other cytokines may also be involved. In SSc patients elevated levels of IL-4, IL-8, IL-10, IL-12, IL-13, and IL-17 were found, suggesting that both B and T cells are involved in the pathogenesis of SSc ([@b25-btt-2-389]; [@b32-btt-2-389]; [@b51-btt-2-389]; [@b21-btt-2-389]). The CD4^+^ T helper cells 2 (Th2) cytokines IL-4, IL-6, and IL-13 stimulate the synthesis of collagen by fibroblasts, leading to excessive scar formation and fibrosis ([@b15-btt-2-389]; [@b67-btt-2-389]). One of the key cytokines involved in tissue fibrosis is transforming growth factor-β (TGF-β) ([@b63-btt-2-389]). Human B lymphocytes, amongst other cells, can be a source of TGF-β and express receptors for TGF-β ([@b31-btt-2-389]). TGF-β promotes collagen deposition and inhibits collagen degradation by decreasing MMPs and increasing the tissue inhibitors of metalloproteinases (TIMP) expression ([@b65-btt-2-389]). Serum TIMP-1, but not MMP-1 levels, are elevated in SSc patients compared with normal controls, indicating that collagen accumulation results from inhibition rather than a decrease in MMPs ([@b71-btt-2-389]).

Flowcytometric analysis of peripheral blood mononuclear cells from SSc patients showed an increased number of naïve B cells, but a decreased number of memory B cells and plasmablasts ([@b54-btt-2-389]). CD19 expression was increased in both naïve and memory B cells, but only memory B cells had an activated phenotype with increased expression of CD80, CD86, and CD95 suggesting chronic activation. Another study showed a 20% higher CD19 and CD21 cell surface density in blood samples from SSc patients compared with normal controls, but similar expression levels of CD20, CD22, and CD40 ([@b52-btt-2-389]). SSc patients have elevated levels of B lymphocyte stimulator (BAFF) ([@b41-btt-2-389]). SSc B cells showed increased levels of BAFF receptor (BAFFR) as well, indicating a pathogenic role of B cells caused by BAFF. BAFF combined with BCR ligation stimulates B cell activity, and was shown to rescue some self-reactive B cells from death ([@b55-btt-2-389]; [@b61-btt-2-389]). Another role of BAFFR is the upregulation of Bcl-2 expression as well as nuclear factor kappa-B (NF-κB) activation, favoring B cell survival ([@b14-btt-2-389]). These studies indicate that BAFF might promote the survival of B cells, thereby contributing to autoimmunity in SSc.

Animal models of SSc
====================

There are several mouse models with features of SSc (summarized in [Table 1](#t1-btt-2-389){ref-type="table"}). The University of California, Davis (UCD) line 200 chickens have numerous immunopathologic and serologic features in common with human scleroderma ([@b22-btt-2-389]). As early as 7 days, lymphocytic infiltration with T and B cells, followed by fibrosis and vascular occlusion of the skin, feet, and comb can be observed ([@b64-btt-2-389]; [@b24-btt-2-389]) Infiltration of CD4^+^ cells precedes that of CD8^+^ and B cells, but during maturation of the skin lesion B cell clusters increase in size, and in mature lesions distinct B and T cell areas are recognized. Also antinuclear antibodies, antibodies to collagen and rheumatoid factor can be detected in this model, as well as antiendothelial cell antibodies ([@b56-btt-2-389]).

In another model, the injection of bleomycin into the skin of mice results in histological dermal changes with thickened and homogenous collagen bundles and cellular infiltrates consisting mainly of CD4^+^ lymphocytes, mast cells and macrophages similar to human scleroderma skin. Bleomycin treatment also leads to the production of serum autoantibodies ([@b68-btt-2-389]; [@b69-btt-2-389]). In MRL/lpr mice deficient for interferon-gamma (IFN-γ) (MRL/lprγR-/-) histological changes are described resembling human scleroderma, such as accumulation of collagen and mononuclear cell infiltration with T and B cells, and macrophages in connective tissue of several organs as well as intima thickening ([@b37-btt-2-389]).

The tight-skin (TSK) mouse is a third model of SSc, and although it does not share all its phenotypic characteristics, autoantibodies are found against SSc-specific target autoantigens including Topo I, fibrillin 1 (Fbn-1), RNA polymerase I, collagen type I, and Fcγ receptors ([@b7-btt-2-389]). It is believed that the TSK phenotype is caused by an internal duplication within the fibrillin 1 gene, resulting in a 3 kb larger transcript compared with the wild-type transcript ([@b57-btt-2-389]). Mice homozygous for this mutation die in utero, while heterozygous (TSK/+) mice survive and develop cutaneous fibrosis, pulmonary emphysema, and cardiac hypertrophy ([@b48-btt-2-389]; [@b20-btt-2-389]). The immunological abnormalities are not well understood, however. The infusion of bone marrow cells of TSK/pa mice into pa/pa littermates resulted in scleroderma-like skin changes with thickening of the deep dermis and a diffuse, interstitial mononuclear infiltrate, consisting of activated lymphocytes, plasma cells and activated macrophages three months later, preceded by a rise in anti-RNA polymerase 1 and Topo 1 autoantibodies ([@b45-btt-2-389]). In another study in the TSK/+ mouse model it was shown that CD19 deficiency resulted in reduction of skin thickness in these mice ([@b49-btt-2-389]). Due to this deficiency, IL-6 production by TSK/+ B cells as well as autoantibody production in TSK/+ mice was decreased, showing that there is a CD19 dependent signalling pathway in B cells contributing to systemic autoimmunity and skin sclerosis in TSK/+ mice.

A more recent mouse model has been a modified model of graft-versus-host (GVH)-induced SSc. The injection of spleen cells from B10.D2 mice into BALB/c mice deficient in mature T and B cells induces a disease resembling SSc with dermal thickening, progressive fibrosis in internal organs, vasculopathy, and presence of autoantibodies ([@b47-btt-2-389]).

Summary
=======

The findings from a number of (pre)clinical studies point to a potential role for B lymphocytes in the pathogenesis of systemic sclerosis. These include abnormal B cell signalling in TSK/+ mice, the presence of B cells and expressed B cell genes in skin biopsies from SSc patients, abnormalities in numbers and activation status of B cells in peripheral blood, the presence of serum autoantibodies and elevated serum levels of cytokines such as IL-6 which correlate with skin fibrosis. B cells could contribute to fibrosis through several mechanisms, depicted in [Figure 2](#f2-btt-2-389){ref-type="fig"}. The stage is set for clinical trials to investigate whether B cell depletion in SSc is effective as in other autoimmune diseases ([@b39-btt-2-389]; [@b9-btt-2-389]; [@b6-btt-2-389]). Preliminary results from a pilot study in SSc patients with rituximab, a chimeric anti-CD20 monoclonal antibody are encouraging ([@b8-btt-2-389]).

Nevertheless, our understanding of the precise contribution of B lymphocytes in the early stages in the pathogenesis of systemic sclerosis is limited, and some of the evidence circumstantial. Further studies are therefore needed to dissect the specific contribution of B lymphocytes in the pathogenesis of systemic sclerosis.
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![CD79a+ B cell infiltrate in dermis of patient with systemic sclerosis (paraffin section, 100x magnification upper figure, 200x magnification lower figure).](btt-2-389f1){#f1-btt-2-389}

![Potential pathways through which B cells mediate or contribute to fibrosis.](btt-2-389f2){#f2-btt-2-389}

###### 

Overview of animal models of scleroderma and comparison with immunological and clinical features of human scleroderma

                   Human scleroderma   GVH SSc in BALB/c mice   UCD-200 chickens   Bleomycin-induced scleroderma   TSK/+ mice
  ---------------- ------------------- ------------------------ ------------------ ------------------------------- ------------
  Autoantibodies   \+                  \+                       \+                 \+                              \+
  Vasculopathy     \+                  \+                       \+                 −                               \+
  Fibrosis                                                                                                         
    Skin           \+                  \+                       \+                 \+                              \+
    Internal       \+                  \+                       \+                 \+                              −
  Inflammation     \+                  \+                       \+                 \+                              −

**Abbreviations:** GVH SSc, graft-versus-host systemic sclerosis; TSK, tight-skin; UCD, University of California, Davis.
